TY  - JOUR

T1  - 2408TiP DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints

JO  - Annals of Oncology

UR  - http://dx.doi.org/10.1016/j.annonc.2023.09.2826

PY  - 2023/10/01

AU  - Jackson-Spence F

AU  - Marin AP

AU  - Puente J

AU  - Molina-Cerrillo J

AU  - Hussain SA

AU  - Ackerman C

AU  - Bonsu N

AU  - Kelly J

AU  - Loriot Y

AU  - Powles TB

AU  - Pulido EG

ED  - 

DO  - DOI: 10.1016/j.annonc.2023.09.2826

PB  - Elsevier BV

VL  - 34

SP  - S1224

EP  - S1225

Y2  - 2024/12/22

ER  -